These two high-quality dividend payers have had very different fortunes recently.

Johnson & Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI®▼ (teclistamab) plus daratumumab for adults with relapsed or refractory multiple myeloma. The decision allows use of the combination as early as second line for patients whose disease has returned or is not responding to prior treatment. The approval is based on Phase 3 data that showed material improvements in patient outcomes versus existing standards of care. This adds another immunotherapy option to Johnson...

Johnson & Johnson just won FDA authorization for OTTAVA, its long-delayed answer to Intuitive Surgical’s two-decade grip on soft-tissue robotics. Management calls it a platform it will build on for a decade.

Starting yield and dividend growth pull $465,000 in two very different directions over a decade, and choosing the wrong one at 53 could cost you far more than the yield gap suggests.

Un juez estadounidense dictamina que los investigadores no difamaron a Johnson & Johnson en un estudio sobre el mesotelioma con talco, lo que marca una victoria clave para el discurso científico en medio de demandas en curso por cáncer de talco.

El régimen para el mieloma múltiple de Johnson & Johnson está ahora aprobado como tratamiento de segunda línea tanto en EE.UU. como en la UE.

En Illinois comenzó un juicio con jurado federal por acusaciones de que los bebés prematuros desarrollaron una afección abdominal grave después de consumir la fórmula para bebés de Mead Johnson.

Johnson & Johnson propone un acuerdo de 5.500 millones de dólares para cerrar demandas por talco. Los detalles del caso judicial.

This week on Market Movers Rx, we break down the biggest biopharma stock movers, from gains at Gilead and Johnson & Johnson to declines for Danaher and Baxter International.

Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens1This immunotherapy doublet regimen demonstrated durable disease control as early as second line, with more than 90% of patients who were progression-free at six months remaining progression-free at three years1BEERSE, BELGIUM, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) has approved an indication extension for TECVAYLI® (teclistamab) in combination with daratumumab for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy. The approval introduces a new treatment option as early as second line for patients living with RRMM.

D.A. Davidson & CO. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 616,117 shares of the company

Boston Trust Walden Corp trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 580,833 shares of the company

Dallas litigation boutique Dean Omar Branham Shirley — with 39 lawyers and 35 support staff — belongs to a small group of firms nationwide that continue to reject Johnson & Johnson’s offers to resolve all its mesothelioma talc litigation through firm-level settlement agreements. Instead, DOBS has taken J&J to trial one case at a time, across the country, facing a roster of major law firms, including Kirkland & Ellis, King & Spalding and Gibson Dunn. And they’re winning.